Shots:

• The P-III RESTORE-IMI 2 study involves assessing of Recarbrio (imipenem 500 mg- cilastatin 500 mg- and relebactam 250 mg) vs Piperacillin/Tazobactam in adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
• The P-III RESTORE-IMI 2 study resulted in meeting its 1EPs & 2EPs of statistical non-inferiority           in Day 28 all-cause mortality and clinical response at early follow-up- respectively
• Recarbio (IV) is a combination of penem antibacterial drug- renal dehydropeptidase inhibitor & beta-lactamase inhibitor- its component Relebactam has received FDA’s QIDP- Fast Track designation for HABP/VABP

Click here to­ read full press release/ article 

Ref: Businesswire | Image: Merck